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CORRESPONDENCE
Re. “The Effect of Deep Venous Stenting on Healing of
Lower Limb Venous Ulcers”
We read with interest Peter Neglen’s commentary on our
paper.1,2
The commentary raises the issue of establishing a diag-
nosis of signiﬁcant obstruction in the absence of expensive
intravascular ultrasound (IVUS) technology. Indeed, this is
the Achilles heel of deep venous disease diagnosis and
perhaps the reason for worldwide underutilization of deep
vein stenting to treat venous ulcers.
Our technique of using trial diagnostic ballooning is
advocated by Raju and Neglen,3 who demonstrated that
trial ballooning helped detect an additional 5% of patients
whose disease was “impervious to even IVUS” and standard
morphological criteria on venography.3 Our own experience
has shown that a combination of venography with selective
trial ballooning helps increase the detection rate to 91%
compared with IVUS alone.4
We agree with Dr Neglen’s comment regarding the use of
high-pressure balloons. We use only semi-compliant bal-
loons for the same reason.4 We agree completely with Dr
Neglen’s comment on the urgent need for an accurate he-
modynamic test of outﬂow obstruction.
We did not give the full CEAP classiﬁcation for all patients
because our study reported only on nonhealing ulcer-
related outcomes, which, by deﬁnition, is C6. We agree
that a reduction in ulcer size is in itself not an accepted
endpoint; however, for large, long-standing ulcers, it reﬂects
a response to therapy. The revised venous clinical severity
score would be the ideal tool to capture this.
We believe this paper reﬂects the “real-world” outcomes
of deep venous stenting for leg ulcers in centers without
access to IVUS.
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Re. ‘Endograft Limb Occlusion in EVAR: Iliac Tortuosity
Quantiﬁed by Three Different Indices on the Basis of
Pre-operative CTA’
This article was with interest at our journal club meeting
and we were delighted with its reported outcome, which
correlates endograft limb occlusion to deﬁned preoperative
iliac tortousity.1
However, there are a few points that we wish to clarify
with the authors of the article. First, this study demon-
strated that the mean  SD of common iliac artery index of
tortuosity (CAI) in patients with graft limb occlusion was
1.31  0.2, which is signiﬁcantly different from the control
group (1.16  0.13). Would the authors of the article be
able to analyse their results further to determine a cut-off
point in CAI that would deﬁne the high-risk patient
group? For example, what is the risk of endograft limb oc-
clusions in a patient with a CAI of 1.25?
It was very useful to assess simply iliac tortuosity using
the double iliac sign, which showed a signiﬁcant difference
from the control group (p < .01). It would be useful to
know the percentage of this ﬁnding in the whole cohort of
patients. And are the authors able to explain why 12% of
the control group had this sign but without endograft limb
occlusion?
We were interested to note that all patients in this study
were treated with endovascular aortic repair (EVAR) using
the Zenith stent graft (Cook Inc., Bloomington, IN, USA)
from January 2000 to December 2010. Were any newer
versions of devices used during this 10-year period and does
this inﬂuence the incidence of limb occlusion? It would be
interesting to know whether there is any particular associ-
ation or pattern that could be identiﬁed in the timing of the
EVARs that are eventually occluded.
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